These are, however, sequence-dependent effects, and, through screening and development, safe and effective ASO medicines have been developed, as exemplified by nusinersen for spinal muscular atrophy (56) and tofersen for SOD1-dependent ALS (57). Here, SOD1 is linked to spinal muscular atrophy.